Citadel Advisors’s Sagimet Biosciences SGMT Stock Holding History

Citadel Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$397K	Sell	51,400 -15,500	-23%	-$105K	﹤0.01%	10446
2026 Q1	$350K	Sell	66,900 -25,700	-28%	-$143K	﹤0.01%	10126
2025 Q4	$548K	Buy	92,600 +47,400	+105%	+$341K	﹤0.01%	8811
2025 Q3	$310K	Sell	45,200 -27,900	-38%	-$226K	﹤0.01%	10293
2025 Q2	$557K	Buy	73,100 +45,800	+168%	+$193K	﹤0.01%	8386
2025 Q1	$89K	Buy	27,300 +19,900	+269%	+$83.5K	﹤0.01%	11630
2024 Q4	$33.3K	Buy	7,400 +7,300	+7,300%	+$37K	﹤0.01%	12774
2024 Q3	$277	Sell	100 -900	-90%	-$2.77K	﹤0.01%	14058
2024 Q2	$3.42K	Buy	+1,000	New	+$4.59K	﹤0.01%	13599

Other funds holding SGMT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors's SGMT Position: Q2 2026 in Review

Citadel Advisors increased its Sagimet Biosciences (SGMT) stake by 53% in Q2 2026, buying an estimated $248K and bringing the position to 104,633 shares worth $809K. The position accounts for ﹤0.01% of the portfolio, ranked #8728.

Citadel Advisors first reported a position in SGMT in Q3 2023 and has held it in 11 quarters since. The position peaked at $4.09M in Q2 2024. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

Citadel Advisors held 104,633 shares of Sagimet Biosciences worth $809K as of Q2 2026.
Citadel Advisors bought 36,460 Sagimet Biosciences shares in Q2 2026, an estimated $248K.
Sagimet Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8728 holding.
Citadel Advisors first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 11 quarters since.
Citadel Advisors's Sagimet Biosciences position peaked at $4.09M in Q2 2024.
122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.